BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 21585245)

  • 1. Interleukin-23: a key cytokine in inflammatory diseases.
    Duvallet E; Semerano L; Assier E; Falgarone G; Boissier MC
    Ann Med; 2011 Nov; 43(7):503-11. PubMed ID: 21585245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis.
    Brentano F; Ospelt C; Stanczyk J; Gay RE; Gay S; Kyburz D
    Ann Rheum Dis; 2009 Jan; 68(1):143-50. PubMed ID: 18276743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
    Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway.
    Liu FL; Chen CH; Chu SJ; Chen JH; Lai JH; Sytwu HK; Chang DM
    Rheumatology (Oxford); 2007 Aug; 46(8):1266-73. PubMed ID: 17569750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
    Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
    Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-23 in the pathogenesis of rheumatoid arthritis.
    Paradowska-Gorycka A; Grzybowska-Kowalczyk A; Wojtecka-Lukasik E; Maslinski S
    Scand J Immunol; 2010 Mar; 71(3):134-45. PubMed ID: 20415779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute CD4+ T lymphocyte-dependent interleukin-1-driven arthritis selectively requires interleukin-2 and interleukin-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, interleukin-6, and leukemia inhibitory factor.
    Lawlor KE; Wong PK; Campbell IK; van Rooijen N; Wicks IP
    Arthritis Rheum; 2005 Dec; 52(12):3749-54. PubMed ID: 16320325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody.
    Beyer BM; Ingram R; Ramanathan L; Reichert P; Le HV; Madison V; Orth P
    J Mol Biol; 2008 Oct; 382(4):942-55. PubMed ID: 18708069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-12, interleukin-23, and psoriasis: current prospects.
    Torti DC; Feldman SR
    J Am Acad Dermatol; 2007 Dec; 57(6):1059-68. PubMed ID: 17706835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells.
    Ma HL; Napierata L; Stedman N; Benoit S; Collins M; Nickerson-Nutter C; Young DA
    Arthritis Rheum; 2010 Feb; 62(2):430-40. PubMed ID: 20112373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice.
    Elson CO; Cong Y; Weaver CT; Schoeb TR; McClanahan TK; Fick RB; Kastelein RA
    Gastroenterology; 2007 Jun; 132(7):2359-70. PubMed ID: 17570211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR-ligand stimulated interleukin-23 subunit expression and assembly is regulated differentially in murine plasmacytoid and myeloid dendritic cells.
    Waibler Z; Kalinke U; Will J; Juan MH; Pfeilschifter JM; Radeke HH
    Mol Immunol; 2007 Mar; 44(7):1483-9. PubMed ID: 17052755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells.
    Křížová L; Kuchař M; Petroková H; Osička R; Hlavničková M; Pelák O; Černý J; Kalina T; Malý P
    Autoimmunity; 2017 Mar; 50(2):102-113. PubMed ID: 28100093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
    Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
    Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signals.
    Sender LY; Gibbert K; Suezer Y; Radeke HH; Kalinke U; Waibler Z
    Mol Immunol; 2010 Mar; 47(6):1255-61. PubMed ID: 20071030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.
    Murphy CA; Langrish CL; Chen Y; Blumenschein W; McClanahan T; Kastelein RA; Sedgwick JD; Cua DJ
    J Exp Med; 2003 Dec; 198(12):1951-7. PubMed ID: 14662908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid.
    Yabu M; Shime H; Hara H; Saito T; Matsumoto M; Seya T; Akazawa T; Inoue N
    Int Immunol; 2011 Jan; 23(1):29-41. PubMed ID: 21131367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways.
    Espígol-Frigolé G; Planas-Rigol E; Lozano E; Corbera-Bellalta M; Terrades-García N; Prieto-González S; García-Martínez A; Hernández-Rodríguez J; Grau JM; Cid MC
    Front Immunol; 2018; 9():809. PubMed ID: 29731755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12-and IL-23 in health and disease.
    Croxford AL; Kulig P; Becher B
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):415-21. PubMed ID: 25130295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.